Advanced search
Publication Cover
Journal of Chemotherapy Volume 36, 2024 - Issue 4
Submit an article Journal homepage
781
Views
0
CrossRef citations to date
0
Altmetric
Case Reports

Case series of metastatic breast cancer patients with visceral crisis treated with CDK4/6 inhibitors

Marissa Meegdesa Department of Internal Medicine, Division of Medical Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The NetherlandsCorrespondence[email protected]
,
Marleen G. A. M. van der Veldeb Department of Internal Medicine, Maxima Medical Center, Veldhoven, The Netherlands
,
Sandra M. E. Geurtsa Department of Internal Medicine, Division of Medical Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands
,
Maartje A. C. E. van Katsa Department of Internal Medicine, Division of Medical Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands
,
M. Wouter Dercksenb Department of Internal Medicine, Maxima Medical Center, Veldhoven, The Netherlands
&
Vivianne C. G. Tjan-Heijnena Department of Internal Medicine, Division of Medical Oncology, GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands
Pages 343-350 | Received 31 Jul 2023, Accepted 02 Nov 2023, Published online: 09 Nov 2023

References

  • Gennari A, André F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–1495. doi: 10.1016/j.annonc.2021.09.019.
  • Sbitti Y, Slimani K, Debbagh A, et al. Visceral crisis means short survival among patients with luminal a metastatic breast cancer: a retrospective cohort study. World J Oncol. 2017;8(4):105–109. doi: 10.14740/wjon1043w.
  • Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol. 2017;28(1):16–33. doi: 10.1093/annonc/mdw544.
  • Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–1649. doi: 10.1016/j.annonc.2020.09.010.
  • Franzoi MA, Saúde-Conde R, Ferreira SC, et al. Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: an 11-year single institutional experience. Breast. 2021;57:86–94. doi: 10.1016/j.breast.2021.03.002.
  • Yang R, Lu G, Lv Z, et al. Different treatment regimens in breast cancer visceral crisis: a retrospective cohort study. Front Oncol. 2022;12:1048781. doi: 10.3389/fonc.2022.1048781.
  • Zhao M, Ramaswamy B. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. World J Clin Oncol. 2014;5(3):248–262. doi: 10.5306/wjco.v5.i3.248.
  • Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016;18(1):17. doi: 10.1186/s13058-015-0661-5.
  • Ballinger TJ, Meier JB, Jansen VM. Current landscape of targeted therapies for Hormone-Receptor positive, HER2 negative metastatic breast cancer. Front Oncol. 2018;8:308. doi: 10.3389/fonc.2018.00308.
  • Spring LM, Wander SA, Andre F, et al. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395(10226):817–827. doi: 10.1016/S0140-6736(20)30165-3.
  • Zhang J, Xu D, Zhou Y, et al. Mechanisms and implications of CDK4/6 inhibitors for the treatment of NSCLC. Front Oncol. 2021;11:676041. doi: 10.3389/fonc.2021.676041.
  • Wagner V, Gil J. Senescence as a therapeutically relevant response to CDK4/6 inhibitors. Oncogene. 2020;39(29):5165–5176. doi: 10.1038/s41388-020-1354-9.
  • Turner NC, Finn RS, Martin M, et al. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol. 2018;29(3):669–680. doi: 10.1093/annonc/mdx797.
  • Martín M, Zielinski C, Ruiz-Borrego M, et al. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study. Eur J Cancer. 2022;168:12–24. doi: 10.1016/j.ejca.2022.03.006.
  • Martin M, Zielinski C, Ruiz-Borrego M, et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL. Ann Oncol. 2021;32(4):488–499. doi: 10.1016/j.annonc.2020.12.013.
  • Giuliano M, Schettini F, Rognoni C, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019;20(10):1360–1369. doi: 10.1016/S1470-2045(19)30420-6.
  • Wilson FR, Varu A, Mitra D, et al. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer. Breast Cancer Res Treat. 2017;166(1):167–177. doi: 10.1007/s10549-017-4404-4.
  • Lu Y-S, Mahidin EIBM, Azim H, et al. Abstract GS1-10: primary results from the randomized phase II RIGHT choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy. Cancer Research. 2023;83(5_Supplement):GS1-10–GS1-10. doi: 10.1158/1538-7445.SABCS22-GS1-10.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.